Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

Y0000802

Dipyridamol für die Peakidentifizierung

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Dipyridamol

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C24H40N8O4
CAS-Nummer:
58-32-2
Molekulargewicht:
504.63
MDL-Nummer:
MFCD00010555
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831157
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

dipyridamole

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

165-166 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

InChIKey

IZEKFCXSFNUWAM-UHFFFAOYSA-N

Angaben zum Gen

human ... PDE10A(10846) , PDE1A(5136) , PDE1B(5153) , PDE1C(5137) , PDE2A(5138) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144) , PDE5A(8654) , PDE6A(5145) , PDE6B(5158) , PDE6C(5146) , PDE6D(5147) , PDE6G(5148) , PDE6H(5149) , PDE7A(5150) , PDE7B(27115) , PDE8A(5151) , PDE8B(8622) , PDE9A(5152) , SLC29A1(2030)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Dipyridamole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

D2850000

Dipyridamol, European Pharmacopoeia (EP) Reference Standard

1220506

Dipyridamol, United States Pharmacopeia (USP) Reference Standard

1220517

Dipyridamol-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1220561

Dipyridamol-verwandte Verbindung F, United States Pharmacopeia (USP) Reference Standard

1220528

Dipyridamol-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1220539

Dipyridamol-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

1220540

Dipyridamol-verwandte Verbindung D, United States Pharmacopeia (USP) Reference Standard

1220559

Dipyridamol-verwandte Verbindung E, United States Pharmacopeia (USP) Reference Standard

BP131

Dipyridamol, British Pharmacopoeia (BP) Reference Standard

BP1102

Dipyridamol-Unreinheit Standard, British Pharmacopoeia (BP) Reference Standard

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Hyung-Hwan Kim et al.
Arteriosclerosis, thrombosis, and vascular biology, 28(3), s39-s42 (2008-01-05)
Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively. By increasing cAMP and cGMP levels in platelets, DP reversibly
Djeven P Deva et al.
Cardiology in the young, 24(5), 822-830 (2013-09-21)
Vasodilator stress perfusion cardiovascular magnetic resonance imaging is a clinically useful tool for detection of clinically significant myocardial ischaemia in adults. We report our 5-year retrospective experience with perfusion cardiovascular magnetic resonance in a large, quarternary adult congenital heart disease
E L L M De Schryver et al.
The Cochrane database of systematic reviews, (3)(3), CD001820-CD001820 (2007-07-20)
Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk reduction compared
Wolfgang G Eisert
Advances in cardiology, 47, 78-86 (2012-08-22)
The antithrombotic activity of dipyridamole was initially discovered in an in vivo experiment about half a century ago. At that time science had not appreciated the complexity of the regulation of local thrombus formation. Inhibition of platelets has been the
Subrata Chakrabarti et al.
Vascular pharmacology, 48(4-6), 143-149 (2008-03-18)
Stroke is a leading cause of morbidity and mortality and the most common cause of neurological disability in older individuals. Prevention of recurrent stroke includes risk factor modification as well as the use of therapies that inhibit platelet activation. One
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.